Skip to main content

Idexx Laboratories company profile

  • IDXX · Nasdaq
  • Biotechnology
  • Health Care Equipment
  • S&P 500
$700.65−0.51%Close 16 Nov 2026 · Market value $54.53B

About Idexx Laboratories

Idexx Laboratories, incorporated in Delaware in 1983, develops, manufactures, and distributes diagnostic products, services, and related instrumentation for the companion animal veterinary, livestock, poultry and dairy, and water testing industries, and also manufactures and sells human medical point-of-care diagnostic products. Its Companion Animal Group offers point-of-care analyzers, SNAP rapid assays, outside reference laboratory services, telemedicine, veterinary practice management software, and diagnostic imaging systems. Its Water segment provides microbiological testing products for drinking, wastewater, and recreational water. Its Livestock, Poultry and Dairy segment provides herd health diagnostic tests and dairy antibiotic residue tests. Customers include veterinarians, government and private laboratories, water utilities, producers, and processors. The company sells directly and through independent distributors and resellers, with a sales presence in the U.S. and in regions including Africa, Asia Pacific, Canada, Europe, and Latin America.

A summary of the business section of the company's latest annual report, filed 20 Feb 2026.

Company facts

TickerIDXX · Nasdaq
SectorBiotechnology
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK874716
Latest annual report10-K, filed 20 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Jonathan J. MazelskyExecutive Chair of the Board · Director323K · < 1%Option exercise, 4 Nov 2026
Brian P. McKeonEVP, CFO and Treasurer52.7K · < 1%Option exercise, 14 Feb 2025
Michael J. LaneExecutive Vice President31.4K · < 1%Open-market sale, 4 Nov 2026
Lawrence D. KingsleyDirector24.1K · < 1%Option exercise, 4 Sep 2026
Stuart M. Essig, PhDDirector12.0K · < 1%Option exercise, 6 May 2025
Andrew EmersonEVP, CFO and Treasurer11.0K · < 1%Shares withheld for tax, 20 Aug 2026
Sophie V. Vandebroek, PhDDirector11.0K · < 1%Option exercise, 7 May 2026
M. Anne SzostakDirector8.5K · < 1%Option exercise, 7 May 2026
Daniel M. JuniusDirector6.9K · < 1%Open-market sale, 4 Nov 2026
Joseph L. (Jay) HooleyDirector522 · < 1%Grant or award, 30 Oct 2026
Karen PeacockDirector333 · < 1%Option exercise, 7 May 2026
FENNELL GEORGEExecutive Vice President—Option exercise, 10 Nov 2026
Underberg Sharon E.EVP, GC &amp; Corporate Secretary—Option exercise, 4 Nov 2026
Hunt NimrataExecutive Vice President—Open-market sale, 3 Mar 2026
Erickson Michael GExecutive Vice President—Option exercise, 19 Feb 2026
Smith Martin AlexanderExecutive Vice President—Option exercise, 14 Feb 2026
Schreck MichaelExecutive Vice President—Shares withheld for tax, 14 Feb 2026
Johnson Michael PerkinsExecutive Vice President—Option exercise, 14 Feb 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

IDXX in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.